Skip to main content
60 Degrees Pharmaceuticals, Inc.SEC 10-Q

DSMB completed interim analysis of severe babesiosis study and recommended completing enrollment

What happened

5 signals in this filing. On October 1, 2026, the independent Data Safety Monitoring Board completed an interim analysis for the severe babesiosis clinical study, found no safety issues, and recommended completing enrollment. The company...

Source

Extracted by Autobound

From the Signal API record
Signal
SEC 10-Q

What this signalsFilings often name leadership changes, deals and spending plans.

Filed
Nov 16, 2026

More SEC 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
1946563
Accession number
0001554855-26-002390
Timeframe
Next quarter
Quarter
Q3
Filing year
2026
Fiscal year end
09/30
Period end date
Sep 30, 2026
Why it matters
Clinical and commercial build-out
Signal category
Strategic

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Nov 17, 2026
signal_type
sec-10q
signal_subtype
clinicalMilestone

Use this data

Get every SEC 10-Q signal for 60 Degrees Pharmaceuticals, Inc. and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at 60 Degrees Pharmaceuticals, Inc. this week?”

  2. Send it to your own tools

    The Signal API returns SEC 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/10f0d932-64c2-4b81-986c-68378f262dbd returns this record as JSON. POST /v1/companies/enrich returns every signal for 60degreespharma.com.

{
  "signal_id": "10f0d932-64c2-4b81-986c-68378f262dbd",
  "signal_type": "sec-10q",
  "signal_subtype": "clinicalMilestone",
  "detected_at": "2026-11-17T07:03:27.034+00:00",
  "company": {
    "name": "60 Degrees Pharmaceuticals, Inc.",
    "domain": "60degreespharma.com"
  },
  "data": {
    "detail": "On October 1, 2026, the independent Data Safety Monitoring Board completed an interim analysis for the severe babesiosis clinical study, found no safety issues, and recommended completing enrollment. The company plans to conclude enrollment at 30 patients and expects endpoint results in January 2027. For sellers: Clinical progression may create opportunities for clinical trial services, regulatory support, and commercial readiness consulting.",
    "metrics": {
      "timeframe": "next_quarter"
    },
    "quarter": "Q3",
    "summary": "DSMB completed interim analysis of severe babesiosis study and recommended completing enrollment",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1946563/000155485526002390/sxtp-20260930.htm",
    "filing_date": "2026-11-16",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Clinical and commercial build-out",
    "signal_category": "strategic"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.